Drug Interactions between amifostine and finasteride / tadalafil
This report displays the potential drug interactions for the following 2 drugs:
- amifostine
- finasteride/tadalafil
Interactions between your drugs
amifostine tadalafil
Applies to: amifostine and finasteride / tadalafil
MONITOR: Concomitant use with antihypertensive agents or drugs with hypotensive effects may increase the risk and severity of hypotension associated with amifostine. Hypotension has been reported frequently in patients treated with amifostine. It is usually transient (lasting from 5 to 15 minutes) and closely associated with amifostine administration, but may persist or become evident hours after administration. Moreover, hypotension can occur despite adequate hydration and positioning of the patient. Significant drops in systolic blood pressure have been reported, in some cases resulting in premature termination of amifostine infusion. In rare cases, sometimes during or after hypotension, patients have experienced tachycardia, bradycardia, dyspnea, apnea, hypoxia, chest pain, myocardial ischemia, renal failure, myocardial infarction, convulsions, unconsciousness, respiratory arrest, and cardiac arrest.
MANAGEMENT: If medically feasible, antihypertensive medications should be interrupted 24 hours prior to amifostine administration. Blood pressure should be closely monitored during and after treatment. In addition to hypotension, transient hypertension or exacerbation of preexisting hypertension may occur from intravenous hydration, discontinuation of antihypertensive medications, or other causes. Patients who continue their hypotensive medication(s) during amifostine therapy should be carefully monitored for the development of hypotension. Clinical symptoms of hypotension are usually quickly reversed by fluid infusion and postural management.
References (2)
- (2001) "Product Information. Ethyol (amifostine)." Alza
- (2002) "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc
Drug and food interactions
tadalafil food
Applies to: finasteride / tadalafil
GENERALLY AVOID: Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors such as tadalafil are used with alcohol, as both are mild systemic vasodilators. In clinical pharmacology studies, more subjects administered alcohol at a dose of 0.7 g/kg (equivalent to approximately 6 ounces of 80-proof vodka in an 80-kg male; consumed within 10 minutes in study subjects, providing blood alcohol levels of 0.08%) in combination with tadalafil 10 or 20 mg single doses had clinically significant decreases in blood pressure than with alcohol alone. There were reports of postural dizziness, and orthostatic hypotension was observed in some. When tadalafil 20 mg was administered with alcohol at a lower dose of 0.6 g/kg (equivalent to approximately 4 ounces of 80-proof vodka in an 80-kg male), orthostatic hypotension was not observed, dizziness occurred with similar frequency relative to alcohol alone, and the hypotensive effects of alcohol were not potentiated. Neither tadalafil nor alcohol affected the plasma concentrations of the other.
GENERALLY AVOID: Coadministration with grapefruit juice is likely to increase the plasma concentrations of tadalafil, which is primarily metabolized by CYP450 3A4. However, the interaction has not been studied. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.
MANAGEMENT: Patients taking tadalafil should avoid consuming large amounts of alcohol (for example, 5 units or more), which may increase the potential for orthostatic signs and symptoms including increase in heart rate, decrease in standing blood pressure, dizziness, and headache. It may also be appropriate to avoid consuming large amounts of grapefruit juice.
References (2)
- (2003) "Product Information. Cialis (tadalafil)." Lilly, Eli and Company
- (2009) "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.